Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integral Perineal Sacrocolpopexy: Expanding Surgical Options for Complex Pelvic Organ Prolapse.

Archivos espanoles de urologia·2026
Same author

Menopause age and hypercholesterolemia comorbidities: a region-wide retrospective cohort study in Andalusia, Spain (2016-2022).

BMJ open·2026
Same author

Heavy burden of soil-transmitted helminth infections in a remote and impoverished indigenous community of Honduras revealed by real time polymerase chain reaction.

Infectious diseases of poverty·2026
Same author

Comparative Performance of Seven Mainstream Large Language Models on the 2022 American College of Radiology Diagnostic Imaging In-Training Examination.

Cureus·2026
Same author

Characterizing the context of spinal cord injury-inclusive community-based organizations to build capacity for research partnerships: An environmental scan.

The journal of spinal cord medicine·2026
Same author

Immunoendocrine Profiles in Neurocysticercosis Patients: A Case-Control Study in Honduras.

Tropical medicine and infectious disease·2026

Related Experiment Video

Updated: Jun 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Emerging drugs for pneumococcal pneumonia.

Vicenç Falcó1, Ana Sánchez, Albert Pahissa

  • 1Infectious Diseases Department , Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. vfalco@vhebron.net

Expert Opinion on Emerging Drugs
|April 14, 2011
PubMed
Summary

Despite available antibiotics, pneumococcal pneumonia mortality remains high. This review examines current and future antibiotic strategies, including β-lactams and fluoroquinolones, to combat resistance and improve treatment outcomes.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Related Experiment Videos

Last Updated: Jun 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • High mortality rates persist for pneumococcal pneumonia despite existing antibiotic treatments.
  • Concerns regarding antibiotic resistance necessitate exploring new indications for current drugs and developing novel agents.
  • β-lactams and fluoroquinolones possess strong antipneumococcal activity and extensive clinical data, potentially delaying the need for new antibiotics.

Purpose of the Study:

  • To review the current landscape of pneumococcal antibiotic resistance.
  • To evaluate available and emerging antimicrobial therapies for pneumococcal pneumonia.
  • To discuss novel therapeutic strategies and combination therapies.

Main Methods:

  • Extensive literature review of manuscripts published within the last 10 years.
  • Comprehensive review of existing and potential antimicrobial agents for pneumococcal pneumonia.
  • Discussion on the role of combination therapy, specifically β-lactams and macrolides.

Main Results:

  • β-lactams remain the primary choice for treating pneumococcal pneumonia.
  • Fluoroquinolones offer an effective alternative therapeutic option.
  • Combination therapy with β-lactams and macrolides may benefit patients with shock or severe sepsis due to immunomodulatory effects.

Conclusions:

  • β-lactams are the preferred agents for pneumococcal pneumonia.
  • Fluoroquinolones provide an excellent alternative treatment.
  • Combination therapy (β-lactams plus macrolides) is recommended for severe cases due to immunomodulatory benefits.